



**For Immediate Release**

**July 27, 2021**

## **Acuitas Therapeutics Names New Director of Chemistry**

**Vancouver, B.C.** – Acuitas Therapeutics is pleased to announce that Steve Arns has joined the team as Director of Chemistry. Dr. Arns comes to the newly created position on the Acuitas executive from adMare BioInnovations, where he most recently was a senior scientist in the medicinal chemistry department. Prior to that, Dr. Arns was a scientist with the Centre for Drug Research and Development.

“Acuitas Therapeutics has experienced exceptional growth over the past year, and Steve’s experience will be a key asset to our future business growth,” said Acuitas Therapeutics’ President & CEO, Dr. Thomas Madden. He added, “Everyone at Acuitas is looking forward to working with Steve and learning from his experience in medicinal chemistry. We are excited about this important new addition to the Acuitas team.”

### **About Acuitas Therapeutics**

Founded in February 2009, Vancouver-based Acuitas Therapeutics ([www.acuitastx.com](http://www.acuitastx.com)) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical companies, biotechnology organizations and academic institutes to advance nucleic acid therapeutics to the clinical trial phase and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology.

-END-